Phase I
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
BioSpace has put together a list of the top 10 indications that have been or are the subject of being researched across the region by pharma companies, academic institutions and other organizations. The trials range from Phase I to Phase III.
San Diego-based Mirati Therapeutics announced the first clinical data from its Phase I/II clinical trial of MRTX849 in solid tumors. MRTX849 is a KRAS G12C inhibitor.
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
GeoVax Labs, Inc. announced its participation in a planned clinical trial led by researchers at American Gene Technologies, to develop a therapy aimed at eliminating HIV from infected people..
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
Calls for increased transparency in clinical trials have been growing and now many medical journals are requiring authors of submitted papers to disclose whether or not they will be sharing clinical trial results.
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
Last week was busy for clinical trial news. Here’s a look.
Findings further validate Cell Pouch and therapeutic cell performance in
Auris Medical Holding Ltd. announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.
PRESS RELEASES